Vaxcyte
PCVX
198 hedge funds and large institutions have $3.9B invested in Vaxcyte in 2022 Q4 according to their latest regulatory filings, with 82 funds opening new positions, 91 increasing their positions, 23 reducing their positions, and 9 closing their positions.
811% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 9
296% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 23
169% more capital invested
Capital invested by funds: $1.45B → $3.9B (+$2.45B)
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
61% more call options, than puts
Call options by funds: $25.1M | Put options by funds: $15.6M
58% more funds holding
Funds holding: 125 → 198 (+73)
0.41% more ownership
Funds ownership: 102.87% → 103.28% (+0.41%)
Top Buyers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$89.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$69.8M |
| 4 |
BlackRock
New York
|
+$63.3M |
| 5 |
Jennison Associates
New York
|
+$55.8M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$122M |
| 2 |
A
Abingworth
London,
United Kingdom
|
-$84.4M |
| 3 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$82.2M |
| 4 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
-$16.9M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$15.7M |
PCVX Hedge Fund Activity: Q4 2022 in Review
198 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2022, worth a combined $3.9B — up 169% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new PCVX positions and 9 closed out — a net gain of 73 holders — while 91 added to existing stakes and 23 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $89.9M. The largest seller was Janus Henderson Group, cutting an estimated $122M.
- 198 institutional investors held Vaxcyte (PCVX) as of Q4 2022, up from 125 in Q3 2022.
- Funds reported $3.9B of Vaxcyte stock for Q4 2022, up 169% quarter-over-quarter.
- 82 funds opened new Vaxcyte positions in Q4 2022 and 9 closed out, a net change of +73 holders.
- The largest Vaxcyte buyer in Q4 2022 was Capital Research Global Investors, an estimated $89.9M added.
- The largest Vaxcyte seller in Q4 2022 was Janus Henderson Group, an estimated $122M sold.
Based on aggregated 13F filings for Q4 2022.